Table 1.
Patient features according to randomization arm
| Characteristic | Dopamine N = 858 |
Norepinephrine N = 821 |
|---|---|---|
| Admission | ||
| Age, mean (SD) | 65 (15) | 65 (14) |
| Sex, n (%) | ||
| Female | 351 (41%) | 372 (45%) |
| Male | 507 (59%) | 449 (55%) |
| APACHE II, median (IQR) | 21 (15, 28) | 20 (15, 27) |
| Cardiomyopathy, n (%)* | ||
| No | 432 (50%) | 399 (49%) |
| Yes | 426 (50%) | 422 (51%) |
| Type of shock, n (%) | ||
| Anaphylactic | 3 (0.3%) | 4 (0.5%) |
| Cardiogenic | 135 (16%) | 145 (18%) |
| Hypovolemic | 138 (16%) | 125 (15%) |
| Other† | 40 (4.7%) | 45 (5.5%) |
| Septic | 542 (63%) | 502 (61%) |
| Mechanical Ventilation, n (%) | 615 (72%) | 580 (71%) |
| Renal replacement therapy, n (%) | 63 (7%) | 61 (7%) |
| SOFA, points, mean (SD) | 9.0 (3.8) | 8.6 (3.8) |
| Respiratory | 2.50 (1.27) | 2.27 (1.27) |
| Cardiovascular | 3.26 (1.01) | 3.16 (1.05) |
| Coagulation | 0.57 (1.00) | 0.55 (0.95) |
| Hepatic | 0.39 (0.89) | 0.38 (0.86) |
| Neurologic | 0.96 (1.46) | 0.89 (1.40) |
| Renal | 1.32 (1.55) | 1.32 (1.58) |
| Outcomes | ||
| New use of renal replacement therapy, n (%) | 64 (7%) | 81 (10%) |
| Arrhythmia | 207 (24%) | 102 (12%) |
| Days Alive and Free of ICU, mean (SD) | 8 (11) | 9 (11) |
| 28-day mortality | 450 (52%) | 398 (48%) |
*Cardiomyopathy as defined by enrolling site. † includes other types of shock that did not fit on other categories and can include obstructive or unspecified shock in the opinion of the enrolling site. For analyses, shock types were categorized in “septic”, “cardiogenic”, and “other”, which includes “other”, “anaphylactic”, and “hypovolemic” types of shock